Executive Summary

Fibromyalgia: Key Metrics in Seven Major Pharmaceutical Markets, 2013–2023

<table>
<thead>
<tr>
<th>2013 Epidemiology</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevalent population</td>
<td>23.7</td>
</tr>
<tr>
<td>Treated population</td>
<td>4.8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2013 Market Sales</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>US</td>
<td>$1,479.4m</td>
</tr>
<tr>
<td>5EU</td>
<td>$149.7m</td>
</tr>
<tr>
<td>Japan</td>
<td>$151.8m</td>
</tr>
<tr>
<td>Total</td>
<td>$1,780.9m</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pipeline Assessment</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of drugs in Phase I–II</td>
<td>4</td>
</tr>
<tr>
<td>Number of first-in-class drugs</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Most Promising Pipeline Drugs</th>
<th>Peak-Year Sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lyrica CR (Pfizer)</td>
<td>$253.1m</td>
</tr>
<tr>
<td>TNX-102 SL (Tonix Pharmaceuticals)</td>
<td>$241.4m</td>
</tr>
<tr>
<td>DS-5565 (Daichii Sankyo)</td>
<td>$296.7m</td>
</tr>
<tr>
<td>TD-9855 (Theravance Biopharma)</td>
<td>$186.8m</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Key Events (2013–2023)</th>
<th>Level of Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eli Lilly’s Cymbalta patent expiry in the US (2013), 5EU (2014), and Japan (2018)</td>
<td>↓↓↓</td>
</tr>
<tr>
<td>Pfizer’s Lyrica patent expiry in the US (2018), 5EU (2014), and Japan (2022)</td>
<td>↓↓↓</td>
</tr>
<tr>
<td>Forest Laboratories/Actavis’ Savella patent expiry in the US (2023) and France (2022)</td>
<td>↓↓↓</td>
</tr>
<tr>
<td>Launch of Pfizer’s Lyrica CR in the US (2016)</td>
<td>↑↑↑</td>
</tr>
<tr>
<td>Launch of Tonix Pharmaceutical’s TNX-102 SL in the US (2017)</td>
<td>↑↑</td>
</tr>
<tr>
<td>Launch of Daiichi Sankyo’s DS-5565 in the US (2018) and 5EU (2019)</td>
<td>↑↑↑</td>
</tr>
<tr>
<td>Launch of Theravance Biopharma’s TD-9855 in the US (2019)</td>
<td>↑↑</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2023 Market Sales</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>US</td>
<td>$1,641.2m</td>
</tr>
<tr>
<td>5EU</td>
<td>$124.2m</td>
</tr>
<tr>
<td>Japan</td>
<td>$147.1m</td>
</tr>
<tr>
<td>Total</td>
<td>$1,912.5m</td>
</tr>
</tbody>
</table>

Source: GlobalData

5EU = France, Germany, Italy, Spain, and UK; 7MM = US, 5EU, and Japan

The table presents the key metrics for fibromyalgia in the seven major pharmaceutical markets (7MM), which are the US, France, Germany, Italy, Spain, the UK, and Japan, during the forecast period from 2013–2023.

Minimal Growth is Expected for the Fibromyalgia Market from 2013 to 2023

Fibromyalgia therapeutic sales growth over the forecast period from 2013 to 2023 is expected to be minimal, at an overall Compound Annual Growth Rate (CAGR) of 0.72%. GlobalData estimated that the fibromyalgia market across the 7MM was valued at approximately $1.8 billion in 2013, the baseline year of the forecast period, and will grow to approximately $1.9 billion by 2023.

The major drivers of the growth of the fibromyalgia market during the forecast period are:

- The introduction of late-stage pipeline therapies, which consist of reformulations of the currently available treatments, and “me-too” products. These will be priced at a premium to the currently marketed therapies
- The increasing prevalent cases of fibromyalgia
Executive Summary

The major barriers to the growth of the fibromyalgia market during the forecast period are:

- The patent expirations of the branded drugs that are approved for the treatment of fibromyalgia in the US and Japan, and are prescribed off-label in the 5EU (France, Germany, Italy, Spain, and the UK). The entry of generic versions of these key drugs will have a negative impact on the revenues of the available branded drugs as well as the pipeline products, following their introduction.

- The lack of late-stage pipeline therapies in development, particularly in the 5EU and Japan.

- Concerns regarding the reduction of healthcare costs as part of government austerity measures, particularly in Europe, which will impede market growth.

Figure below illustrates the global sales for fibromyalgia by region during the forecast period.

**Global Fibromyalgia Sales by Region, 2013–2023**

<table>
<thead>
<tr>
<th>Year</th>
<th>Total: $bn</th>
<th>US</th>
<th>France</th>
<th>Germany</th>
<th>Italy</th>
<th>Spain</th>
<th>UK</th>
<th>Japan</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>$1.8bn</td>
<td>83%</td>
<td>2%</td>
<td>4%</td>
<td>1.3%</td>
<td>1.4%</td>
<td>9%</td>
<td>0.6%</td>
</tr>
<tr>
<td>2023</td>
<td>$1.9bn</td>
<td>86%</td>
<td>8%</td>
<td>1%</td>
<td>1.0%</td>
<td>1.2%</td>
<td>8%</td>
<td>0.6%</td>
</tr>
</tbody>
</table>

Source: GlobalData
Executive Summary

New Drugs with Improved Efficacy, Safety, and Convenience to Expand the Fibromyalgia Pipeline

In 2007, Pfizer’s Lyrica (pregabalin) was the first drug to secure approval by the Food and Drug Administration (FDA) for the treatment of fibromyalgia, and was subsequently approved in Japan in 2012. Following on from this were the FDA approvals of Eli Lilly’s Cymbalta (duloxetine) in 2008, and Forest Laboratories/Actavis’ Savella (milnacipran) in 2009. While none of these therapies has been approved for fibromyalgia in the 5EU, they are available for other indications, and are therefore prescribed as off-label therapies. Lyrica, Cymbalta, and Savella currently lead the fibromyalgia market in terms of sales across the 7MM. In addition to these products, there are a limited number of other treatments available, including antidepressants, anti-epileptics, opioids, and muscle relaxants, which are mainly genericized and are used off-label.

Since the launch of the three leading treatments, the fibromyalgia market has been fairly inactive in terms of the entry of new therapies. Of the leading players, only Pfizer has decided to keep its stake in the market by developing a follow-up reformulation product, which is a controlled-release (CR) version of Lyrica (Lyrica CR). Over the forecast period, the three branded products will be exposed to severe sales erosion from generic competitors. Further jeopardizing the position of these mature brands will be the launch of other late-stage pipeline products, which are aimed at improving their efficacy, safety, and convenience profiles. Another drug reformulation in development is Tonix Pharmaceutical’s TNX-102 SL, which is a lower-dose formulation of the widely-used cyclobenzaprine. A number of “me-too” therapies are also on the horizon, including Daiichi Sankyo’s anti-epileptic, DS-5565, and Theravance Biopharma’s antidepressant, TD-9855.

Figure below provides an analysis of the company portfolio gap in fibromyalgia during the forecast period.
Executive Summary

Limited Number of Approved Products in the Fibromyalgia Market

The fibromyalgia landscape is not yet well-established, with only a handful of drugs being accessible to patients. Of these drugs, three are approved in the US, one in Japan, and none in the 5EU. Consequently, there is a high level of off-label usage of these products, particularly in the 5EU. Off-label drug usage raises reimbursement issues, particularly in the 5EU, which has created an urgent need for the approval of new fibromyalgia therapies. Furthermore, the currently approved drugs for fibromyalgia have modest efficacy and/or safety, underscoring the need for more efficacious and safer therapies that have advantages over the existing treatments.

This clinical unmet need may be addressed by the four products (reformulations and “me-too” products) that have the potential to launch by 2023; however, not all of these products will be commercialized across all the 7MM. Although they lack novelty, it is hoped that these new therapies will provide a wider range of treatments with better efficacy, safety, and convenience profiles. Therefore, the level of unmet need in the fibromyalgia market landscape during the forecast period will continue to be relatively high.

Major Opportunities for New Entrants

By the end of the forecast period in 2023, an additional four products will have been added to the fibromyalgia arena. All four will be launched in the US, only one in the 5EU, and none in Japan. Some of these products are reformulations of existing products, while others are “me-too” products. Ultimately, the companies developing these drugs are using these strategies with the aim to offer safer and more effective therapies in order to address the significant unmet need in treating fibromyalgia patients. The majority of these companies are emerging players in the fibromyalgia market, and are hoping to gain a share of the market.

Although the range of available fibromyalgia therapies is currently limited, the late-stage pipeline will not be able to greatly expand the treatment options in all 7MM. On the other hand, the early-stage clinical trials may be able address this issue by providing novel therapies. Given the low level of research activity in this disease area, there are considerable commercial opportunities available for drug developers.

Pipeline Products Will Leave the Fibromyalgia Landscape Relatively Untapped

Although the potential introduction of new therapies will narrowly increase the treatment choices for fibromyalgia, the launches of different products in different countries (four in the US, and one in the 5EU) will mean that some countries, such as the 5EU and Japan, will see minimal change in the physician adoption rate. Furthermore, these therapies are not expected to revolutionize the fibromyalgia market, given that by the time the reformulations of the existing products...
Executive Summary

(Lyrica CR and TNX-102 SL) are launched and established, there will be inexpensive generic equivalents available. While the “me-too” therapies (DS-5565 and TD-9855) may gain a better share of the market, this will depend on the timing of their entry, such that TD-9855, being the last product to enter the US market during the forecast period, will face intense competition for patient share. Daiichi Sankyo’s DS-5565 is the only product with potential commercialization in both the US (2018) and 5EU (2019) fibromyalgia markets. GlobalData forecasts that its combined sales will secure its position as the highest-selling pipeline agent by 2023, with sales reaching approximately $296.7m.

Figure below provides a competitive assessment of the late-stage pipeline agents in fibromyalgia during the forecast period.

| Competitive Assessment of Late-Stage Pipeline Agents in Fibromyalgia, 2013–2023 |
|----------------------------------|----------------------------------|
| **Commercial Attributes**       | **Clinical Attributes**          |
| Low                              | Low                              |
| High                             | High                             |
| Daichi Sankyo’s DS-5565          | Pfizer’s Lyrica CR               |
| Theravance Biopharma’s TD-9855   | Theravance Biopharma’s TD-9855   |
| Tanox Pharmaceutical’s TNX-102 SL| Tanox Pharmaceutical’s TNX-102 SL|

What Do Physicians Think?

Physicians interviewed by GlobalData acknowledged that more effective and safer medications are needed for the fibromyalgia patient population, as well as the fact that the approval of new drugs is a high unmet need in the 5EU.

“We need to have treatments that can address [the] different components [of the disease] more precisely. Like I said, sleep modes and so on, because they’re critical [to address] for chronic pain disorder; particularly sleep is one of the most critical ones.”

US Key Opinion Leader

“The available drugs are in no way perfect; they have side effects. The effect sizes, at least in the clinical trials, are very low, so there is proof that they improve—that they improve the pain, that they improve depression, sleep, and so [on], but to a small degree... So, there is a need for [more] effective drugs.”

OUS Key Opinion Leader

“If the pipeline drugs receive approval, it would be much easier [for reimbursement] — yes. That would solve a big problem.”

OUS Key Opinion Leader

Note: Bubble size represents approximate peak-year sales of pipeline drug

Source: GlobalData
Executive Summary

“We have no authorization, [no] official authorization, for using specific drugs in fibromyalgia. We are able — allowed to use general pain treatments, and so forth.”

OUS Key Opinion Leader

“I also hope [that the manufacturers of] pharmaceuticals would provide higher quality and [more] affordable drugs soon.”

OUS Key Opinion Leader

In terms of new drugs for fibromyalgia, physicians had mixed views about the reformulation of Lyrica as a CR agent, and expressed concerns about the effect of Lyrica CR’s pricing on their prescribing patterns.

“I would prefer the controlled-release [formulation of Lyrica] because of the pharmacokinetics…. but it’s a price issue, and I’m not sure the pricing would — the benefits will make up [for] the increased cost for this [drug].”

US Key Opinion Leader

“I don’t know whether I would view that [Lyrica CR] as a sort of a major advancement.”

OUS Key Opinion Leader

“I think it’s [Lyrica CR] a good idea. Again, pregabalin has been a time-tested drug. And yes, one daily dose will be useful in terms of [improving] compliance of the patients. [However,] it would depend on the cost.”

OUS Key Opinion Leader

“I’m not sure how much better it [Lyrica CR] will be than the simple Lyrica, but it should be at least as good. It should be easier to use, maybe better-tolerated because of the slow release.”

OUS Key Opinion Leader

Physicians were also unsure of the beneficial effects that another reformulation, that of cyclobenzaprine (TNX-102 SL), would have on their patients.

“Yes, I’m not so sure. I mean, I have never had any problems with low-dose cyclobenzaprine [that I would want] to prescribe this [reformulation] without a particular formulary condition. So, I’m not sure [I would prescribe it]. I’m really not.”

US Key Opinion Leader

“I think, in general, it [the reformulation of cyclobenzaprine] makes it easy for folks. I don’t really have a strong feeling about the route of administration. I guess I’m thinking more about its mechanism, and the mechanism makes sense.”

US Key Opinion Leader

In addition, physicians said they believed that there is room for the introduction of “me-too” products to the fibromyalgia market.

“Yes, there are markets [for ‘me-too’ drugs], particularly if they have slightly different effects and different side effects compared to Lyrica.”

US Key Opinion Leader
Executive Summary

“If this was an alpha-2-delta ligand that either has fewer side effects than pregabalin or has a higher effect size in treating pain and sleep disorder—yes, there would be room [for it in the market].”

OUS Key Opinion Leader
Table of Contents

1 Table of Contents

1 Table of Contents ....................................................................................................................... 9

1.1 List of Tables .................................................................................................................... 15

1.2 List of Figures ................................................................................................................... 18

2 Introduction ............................................................................................................................... 20

2.1 Catalyst ............................................................................................................................. 20

2.2 Related Reports ................................................................................................................ 20

2.3 Upcoming Related Reports ............................................................................................... 21

3 Disease Overview ..................................................................................................................... 22

3.1 Etiology and Pathophysiology ........................................................................................... 22

3.1.1 Etiology ......................................................................................................................... 22

3.1.2 Pathophysiology ............................................................................................................ 24

3.2 Classification ..................................................................................................................... 28

3.3 Symptoms ......................................................................................................................... 28

3.4 Quality of Life .................................................................................................................... 29

4 Epidemiology ............................................................................................................................ 30

4.1 Disease Background ......................................................................................................... 30

4.2 Risk Factors and Comorbidities ....................................................................................... 30

4.3 Global Trends .................................................................................................................... 32

4.3.1 US ................................................................................................................................. 34

4.3.2 5EU ............................................................................................................................. 34

4.3.3 Japan ........................................................................................................................... 34
# Table of Contents

4.4 Forecast Methodology ....................................................................................................... 35  
4.4.1 Sources Used ................................................................................................................ 35  
4.4.2 Sources Not Used ......................................................................................................... 39  
4.4.3 Forecast Assumptions and Methods – Total Prevalent Cases of Fibromyalgia .......... 40  
4.4.4 Forecast Assumptions and Methods – Fibromyalgia Pain Severity ............................ 42  
4.5 Epidemiological Forecast for Fibromyalgia (2013–2023) ................................................... 43  
4.5.1 Total Prevalent Cases of Fibromyalgia .......................................................................... 43  
4.5.2 Age-Specific Total Prevalent Cases of Fibromyalgia ..................................................... 45  
4.5.3 Sex-Specific Total Prevalent Cases of Fibromyalgia ..................................................... 47  
4.5.4 Age-Standardized Total Prevalence of Fibromyalgia ..................................................... 49  
4.5.5 Total Prevalent Cases of Fibromyalgia by Pain Severity ................................................ 51  
4.6 Discussion ........................................................................................................................ 52  
4.6.1 Epidemiological Forecast Insight ................................................................................... 52  
4.6.2 Limitations of the Analysis ............................................................................................. 54  
4.6.3 Strengths of the Analysis ............................................................................................... 54  
5 Disease Management ............................................................................................................... 56  
5.1 Diagnosis and Treatment Overview .................................................................................. 56  
5.1.1 Diagnosis ...................................................................................................................... 56  
5.1.2 Treatment Guidelines and Leading Prescribed Drugs ................................................... 58  
5.1.3 Clinical Practice ............................................................................................................. 60  
5.2 US ..................................................................................................................................... 62  
5.3 France .............................................................................................................................. 64  
5.4 Germany .......................................................................................................................... 65
Table of Contents

5.5 Italy ................................................................................................................................... 67
5.6 Spain .................................................................................................................................. 69
5.7 UK..................................................................................................................................... 71
5.8 Japan .................................................................................................................................. 73

6 Competitive Assessment .......................................................................................................... 76
6.1 Overview ........................................................................................................................... 76
6.2 Product Profiles ................................................................................................................. 77
6.2.1 Cymbalta (duloxetine) ................................................................................................... 77
6.2.2 Savella (milnacipran) ..................................................................................................... 81
6.2.3 Lyrica (pregabalin) ........................................................................................................ 86
6.2.4 Neurontin (gabapentin) .................................................................................................. 91
6.2.5 Other Antidepressants ................................................................................................... 94
6.2.6 Opioids ........................................................................................................................ 102
6.2.7 Cyclobenzaprine ......................................................................................................... 107

7 Unmet Need and Opportunity ................................................................................................. 111
7.1 Overview ........................................................................................................................... 111
7.2 More Effective and Well-Tolerated Therapies .................................................................... 112
7.2.1 Unmet Need ................................................................................................................ 112
7.2.2 Gap Analysis ................................................................................................................. 114
7.2.3 Opportunity .................................................................................................................. 114
7.3 Increased Drug Approvals ................................................................................................. 114
7.3.1 Unmet Need ................................................................................................................ 114
7.3.2 Gap Analysis ................................................................................................................. 115
# Table of Contents

7.3.3 Opportunity .......................................................................................................................... 116

7.4 Increased Physician/Patient Awareness and Earlier Diagnosis .......................................... 116
  7.4.1 Unmet Need .......................................................................................................................... 116
  7.4.2 Gap Analysis ....................................................................................................................... 117
  7.4.3 Opportunity ........................................................................................................................ 117

7.5 Diagnostic Tools ....................................................................................................................... 118
  7.5.1 Unmet Need ........................................................................................................................ 118
  7.5.2 Gap Analysis ....................................................................................................................... 119
  7.5.3 Opportunity ........................................................................................................................ 119

8 Pipeline Assessment .................................................................................................................. 120
  8.1 Overview ................................................................................................................................ 120
  8.2 Clinical Trial Mapping ............................................................................................................ 120
    8.2.1 Clinical Trials by Class of Therapy ................................................................................ 120
  8.3 Promising Drugs in Clinical Development ............................................................................ 121
    8.3.1 Lyrica CR (pregabalin) ..................................................................................................... 124
    8.3.2 DS-5565 (mirogabalin) .................................................................................................... 130
    8.3.3 TNX-102 SL (cyclobenzaprine) ...................................................................................... 136
    8.3.4 TD-9855 .......................................................................................................................... 144
  8.4 Other Drugs in Development ................................................................................................. 149

9 Current and Future Players ........................................................................................................ 150
  9.1 Overview ................................................................................................................................ 150
  9.2 Trends in Corporate Strategy ................................................................................................. 153
  9.3 Company Profiles ................................................................................................................... 154
# Table of Contents

9.3.1 Pfizer .............................................................................................................................. 154  
9.3.2 Eli Lilly .......................................................................................................................... 157  
9.3.3 Forest Laboratories (Actavis) ...................................................................................... 160  
9.3.4 Daiichi Sankyo ............................................................................................................ 163  
9.3.5 Tonix Pharmaceuticals ................................................................................................ 166  
9.3.6 Theravance Biopharma ............................................................................................... 169  

10 Market Outlook .................................................................................................................. 173  

10.1 Global Markets ............................................................................................................... 173  
10.1.1 Forecast ...................................................................................................................... 173  
10.1.2 Drivers and Barriers – Global Issues ........................................................................ 177  
10.2 United States .................................................................................................................. 178  
10.2.1 Forecast ...................................................................................................................... 178  
10.2.2 Key Events .................................................................................................................. 182  
10.2.3 Drivers and Barriers .................................................................................................... 182  
10.3 5EU ................................................................................................................................... 183  
10.3.1 Forecast ...................................................................................................................... 183  
10.3.2 Key Events .................................................................................................................. 188  
10.3.3 Drivers and Barriers .................................................................................................... 188  
10.4 Japan .............................................................................................................................. 190  
10.4.1 Forecast ...................................................................................................................... 190  
10.4.2 Key Events .................................................................................................................. 193  
10.4.3 Drivers and Barriers .................................................................................................... 193  

11 Appendix ............................................................................................................................ 195
# Table of Contents

11.1 Bibliography .................................................................................................................... 195
11.2 Abbreviations .................................................................................................................. 205
11.3 Methodology ................................................................................................................... 210
11.4 Forecasting Methodology ................................................................................................. 210
11.4.1 Diagnosed Fibromyalgia Patients ................................................................................ 210
11.4.2 Percentage of Drug-Treated Patients .......................................................................... 211
11.4.3 Drugs Included in Each Therapeutic Class ................................................................. 211
11.4.4 Launch and Patent Expiry Dates ................................................................................. 211
11.4.5 General Pricing Assumptions ...................................................................................... 212
11.4.6 Individual Drug Assumptions ....................................................................................... 213
11.4.7 Generic Erosion .......................................................................................................... 216
11.4.8 Pricing of Pipeline Agents ............................................................................................ 216
11.5 Primary Research – KOLs Interviewed for This Report ................................................... 218
11.6 Primary Research – Prescriber Survey ........................................................................... 219
11.7 About the Authors ........................................................................................................... 220
11.7.1 Analyst ........................................................................................................................ 220
11.7.2 Therapy Area Director ................................................................................................. 220
11.7.3 Epidemiologist ............................................................................................................. 221
11.7.4 Global Head of Healthcare .......................................................................................... 221
11.8 About GlobalData ............................................................................................................ 222
11.9 Disclaimer ....................................................................................................................... 222
Table of Contents

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for Fibromyalgia ................................................................. 31
Table 2: Comparison of the ACR Criteria for Fibromyalgia Classification ........................................... 33
Table 3: 7MM, Sources of Total Prevalence Data Used to Forecast the Total Prevalent Cases of Fibromyalgia .................................................................................................................. 35
Table 4: 7MM, Sources of Fibromyalgia Pain Severity Data Used to Forecast the Total Prevalent Cases of Fibromyalgia Segmented by Pain Severity ............................................................................. 36
Table 5: 7MM, Total Prevalent Cases of Fibromyalgia, Ages ≥10 Years, Both Sexes, N, Selected Years 2013–2023 .......................................................................................................................... 44
Table 6: 7MM, Age-Specific Total Prevalent Cases of Fibromyalgia, Both Sexes, N (Row %), 2013 .......... 46
Table 7: 7MM, Sex-Specific Total Prevalent Cases of Fibromyalgia, Ages ≥10 Years, N (Row %), 2013 .... 48
Table 8: 7MM Total Prevalent Cases of Fibromyalgia, N (%), by Pain Severity, Both Sexes, Ages ≥10 Years, 2013 ................................................................................................................................. 51
Table 9: Treatment Guidelines for Fibromyalgia ...................................................................................... 59
Table 10: Most Commonly Prescribed Drugs for Fibromyalgia by Class in the Global Markets, 2014 ....... 60
Table 11: Diagnosis and Treatment of Fibromyalgia, Country Profile – US ........................................... 63
Table 12: Diagnosis and Treatment of Fibromyalgia, Country Profile – France ........................................ 65
Table 13: Diagnosis and Treatment of Fibromyalgia, Country Profile – Germany .................................... 67
Table 14: Diagnosis and Treatment of Fibromyalgia, Country Profile – Italy ............................................ 69
Table 15: Diagnosis and Treatment of Fibromyalgia, Country Profile – Spain ........................................ 71
Table 16: Diagnosis and Treatment of Fibromyalgia, Country Profile – UK ............................................. 73
Table 17: Diagnosis and Treatment of Fibromyalgia, Country Profile – Japan ......................................... 75
Table 18: Leading Branded Drug Treatments for Fibromyalgia in the 7MM, 2014 ................................. 77
Table 19: Product Profile – Cymbalta ........................................................................................................ 78
Table 20: Cymbalta SWOT Analysis, 2014 ............................................................................................. 80
Table of Contents

Table 21: Global Sales Forecasts ($m) for Cymbalta, 2013–2023 .......................................................... 81
Table 22: Product Profile – Savella ........................................................................................................... 82
Table 23: Savella SWOT Analysis, 2014 .................................................................................................. 85
Table 24: Global Sales Forecasts ($m) for Savella, 2013–2023 .............................................................. 86
Table 25: Product Profile – Lyrica ............................................................................................................ 87
Table 26: Lyrica SWOT Analysis, 2014 .................................................................................................... 90
Table 27: Global Sales Forecasts ($m) for Lyrica, 2013–2023 ............................................................... 91
Table 28: Product Profile – Neurontin ....................................................................................................... 92
Table 29: Neurontin SWOT Analysis, 2014 ............................................................................................ 93
Table 30: Global Sales Forecasts ($m) for Gabapentin, 2013–2023 ......................................................... 94
Table 31: Product Profile – Other Antidepressants Frequently Used in the Treatment of Fibromyalgia........ 97
Table 32: Other Antidepressants Used in the Treatment of Fibromyalgia, SWOT Analysis, 2014 ............ 101
Table 33: Global Sales Forecasts ($m) for Other Antidepressants, 2013–2023 ....................................... 102
Table 34: Product Profile – Opioids ......................................................................................................... 104
Table 35: Opioids SWOT Analysis, 2014 ................................................................................................ 106
Table 36: Global Sales Forecasts ($m) for Opioids, 2013–2023 ............................................................ 107
Table 37: Product Profile – Cyclobenzaprine ............................................................................................ 108
Table 38: Cyclobenzaprine SWOT Analysis, 2014 ................................................................................. 110
Table 39: Global Sales Forecasts ($m) for Cyclobenzaprine, 2013–2023 ................................................. 110
Table 40: Unmet Need and Opportunity in Fibromyalgia ....................................................................... 112
Table 41: Comparison of Therapeutic Classes in Development for Fibromyalgia, 2014 ................. 123
Table 42: Product Profile – Lyrica CR (pregabalin) ................................................................................. 125
Table 43: Lyrica CR SWOT Analysis, 2014 ............................................................................................ 129
Table 44: Global Sales Forecasts ($m) for Lyrica CR, 2013–2023 ......................................................... 130
# Table of Contents

Table 45: Product Profile – DS-5565 (mirogabalin) ................................................................. 131
Table 46: DS-5565 SWOT Analysis, 2014 .................................................................................. 135
Table 47: Global Sales Forecasts ($m) for DS-5565, 2013–2023 ............................................... 136
Table 48: Product Profile – TNX-102 SL (Cyclobenzaprine) .................................................... 138
Table 49: SWOT Analysis TNX-102 SL, 2014 ........................................................................... 143
Table 50: Global Sales Forecasts ($m) for TNX-102 SL, 2013–2023 ......................................... 144
Table 51: Product Profile – TD-9855 ...................................................................................... 145
Table 52: TD-9855 SWOT Analysis, 2014 .............................................................................. 148
Table 53: Global Sales Forecasts ($m) for TD-9855, 2013–2023 ............................................. 149
Table 54: Drugs in Development for Fibromyalgia, 2014 ...................................................... 149
Table 55: Key Companies in the Fibromyalgia Market in the 7MM, 2014 ................................. 151
Table 56: Pfizer’s Fibromyalgia Portfolio Assessment, 2014 .................................................... 155
Table 57: Eli Lilly's Fibromyalgia Portfolio Assessment, 2014 .................................................. 158
Table 58: Forest Laboratories’ (Actavis) Fibromyalgia Portfolio Assessment, 2014 .................. 161
Table 59: Daiichi Sankyo’s Fibromyalgia Portfolio Assessment, 2014 .................................. 164
Table 60: Tonix Pharmaceutical’s Fibromyalgia Portfolio Assessment, 2014 ......................... 167
Table 61: Theravance Biopharma’s Fibromyalgia Portfolio Assessment, 2014 ....................... 170
Table 62: Global Sales Forecasts ($m) for Fibromyalgia, 2013–2023 ........................................ 175
Table 63: Global Fibromyalgia Market – Drivers and Barriers, 2013–2023 ............................ 177
Table 64: Sales Forecasts ($m) for Fibromyalgia in the US, 2013–2023 ................................... 180
Table 65: Key Events Impacting Sales for Fibromyalgia in the US, 2013–2023 ..................... 182
Table 66: Fibromyalgia Market in the US – Drivers and Barriers, 2013–2023 ....................... 182
Table 67: Sales Forecasts ($m) for Fibromyalgia in the 5EU, 2013–2023 ............................... 185
Table 68: Key Events Impacting Sales for Fibromyalgia in the 5EU, 2013–2023 ................... 188
Table of Contents

Table 69: Fibromyalgia Market in the 5EU – Drivers and Barriers, 2013–2023 ................................................ 188
Table 70: Sales Forecasts ($m) for Fibromyalgia in Japan, 2013–2023 .......................................................... 191
Table 71: Key Events Impacting Sales for Fibromyalgia in the US, 2013–2023 .............................................. 193
Table 72: Fibromyalgia Market – Drivers and Barriers, 2013-2023 ............................................................... 193
Table 73: Key Launch Dates for Fibromyalgia Drugs in the 7MM ................................................................. 211
Table 74: Key Patent Expiries for the Marketed Drugs Indicated for Fibromyalgia ....................................... 212
Table 75: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country .................................................... 219

1.2 List of Figures

Figure 1: 7MM, Total Prevalent Cases of Fibromyalgia Ages ≥10 Years, Both Sexes, N, 2013–2023 .......... 45
Figure 2: 7MM, Age-Specific Total Prevalent Cases of Fibromyalgia, Both Sexes, N, 2013 .................... 47
Figure 3: 7MM, Sex-Specific Total Prevalent Cases of Fibromyalgia, Ages ≥10 Years, N, 2013 ............... 49
Figure 4: 7MM, Age-Standardized Total Prevalence of Fibromyalgia (%), Ages ≥10 Years, by Sex, 2013 ... 50
Figure 5: 7MM Total Prevalent Cases of Fibromyalgia (N), by Pain Severity, Both Sexes, Ages ≥10 Years, 2013 ........................................................................................................................................ 52
Figure 6: Fibromyalgia Tender Points ............................................................................................................ 57
Figure 7: Fibromyalgia Therapeutics - Class of Therapy, 2014 ................................................................. 121
Figure 8: Fibromyalgia – Phase II–III Pipeline, 2014 .................................................................................. 122
Figure 9: Competitive Assessment of Late-Stage Pipeline Agents in Fibromyalgia, 2013–2023 .......... 123
Figure 10: Clinical and Commercial Positioning of Lyrica CR ............................................................ 128
Figure 11: Clinical and Commercial Positioning of DS-5565 ................................................................ 134
Figure 12: Clinical and Commercial Positioning of TNX-102 SL ........................................................... 142
Figure 13: Clinical and Commercial Positioning of TD-9855 ................................................................. 148
Figure 14: Global Sales of Branded Products for Fibromyalgia by Company, 2013–2023 ...................... 152
# Table of Contents

Figure 15: Company Portfolio Gap Analysis in Fibromyalgia, 2013–2023 ........................................................................................................................................ 153  
Figure 16: Pfizer’s SWOT Analysis in Fibromyalgia, 2013–2023 ........................................................................................................................................ 157  
Figure 17: Eli Lilly SWOT Analysis in Fibromyalgia, 2013–2023 ........................................................................................................................................ 160  
Figure 18: Forest Laboratories (Actavis) SWOT Analysis in Fibromyalgia, 2013–2023 ........................................................................................................................................ 163  
Figure 19: Daiichi Sankyo SWOT Analysis in Fibromyalgia, 2013–2023 ........................................................................................................................................ 166  
Figure 20: Tonix Pharmaceuticals SWOT Analysis in Fibromyalgia, 2013–2023 ........................................................................................................................................ 169  
Figure 21: Theravance Biopharma SWOT Analysis in Fibromyalgia, 2013–2023 ........................................................................................................................................ 172  
Figure 22: Global Sales for Fibromyalgia by Region, 2013–2023 ........................................................................................................................................ 176  
Figure 23: Sales for Fibromyalgia in the US by Drug Class, 2013–2023 ........................................................................................................................................ 181  
Figure 24: Sales for Fibromyalgia in the 5EU by Drug Class, 2013–2023 ........................................................................................................................................ 186  
Figure 25: Sales for Fibromyalgia in the 5EU by Country, 2013–2023 ........................................................................................................................................ 187  
Figure 26: Sales for Fibromyalgia in Japan by Drug Class, 2013–2023 ........................................................................................................................................ 192
Introduction

2 Introduction

2.1 Catalyst

The fibromyalgia market is relatively new and is not yet well-established. Three drugs currently dominate the sales across the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan), and form the core treatment options — Lyrica (pregabalin), Cymbalta (duloxetine), and Savella (milnacipran) — which are all approved in the US, while only Lyrica is approved in Japan. Since these drugs are also available in the 5EU (France, Germany, Italy, Spain, and the UK) for other indications, they are prescribed as off-label therapies for fibromyalgia. Apart from these drugs, a handful of other genericized products are also used off-label, including antidepressants, anti-epileptics, opioids, and muscle relaxants. Since the launch of Lyrica, Cymbalta, and Savella, the fibromyalgia market has remained static in terms of the entry of new therapies. Although the currently available products can provide an effective treatment regimen, there are ample opportunities for the development of new treatment choices that can expand the medications that are available to patients and provide improvements in efficacy, safety, and compliance. By 2023, the market will have entered a new phase with the patent expiries of the currently leading drugs and the introduction of four potential promising late-stage pipeline products: a reformulation of Lyrica, called Lyrica CR; a formulation of cyclobenzaprine, called TNX-102 SL; an anti-epileptic, DS-5565; and an antidepressant, TD-9855. These new products will help drive market growth and offset some of the effects of the patent expiries of the leading brands during the forecast period.

2.2 Related Reports

- GlobalData (2014). Neuropathic Pain – Global Drug Forecast and Market Analysis to 2023, April 2014, GDHC003PIDR
- GlobalData (2014). Major Depressive Disorder – Global Drug Forecast and Market Analysis to 2023, April 2014, GDHC003PIDR
2.3 Upcoming Related Reports

Appendix

11.8 About GlobalData

GlobalData is a leading global provider of business intelligence in the healthcare industry. GlobalData provides its clients with up-to-date information and analysis on the latest developments in drug research, disease analysis, and clinical research and development. Our integrated business intelligence solutions include a range of interactive online databases, analytical tools, reports, and forecasts. Our analysis is supported by a 24/7 client support and analyst team.

GlobalData has offices in New York, San Francisco, Boston, London, India, Korea, Japan, Singapore, and Australia.

11.9 Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher, GlobalData.